Business
Enveric Biosciences Announces Patent Issuance
CAMBRIDGE, Mass., December 29, 2025--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced the issuance of U.S. Patent No. 12,492,179 entitled, "Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives" (the "‘179 patent"), with claims to compositions and methods of treatment for novel molecules with the potential to be develope
About this update from Enveric Biosciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/7c5658de8d5fc93c4b63ab8d2347959a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/d9zJPIjygpx14ha34pRVAQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/7c5658de8d5fc93c4b63ab8d2347959a","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/0EdbGqK2fVVne.T3pzQL5Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/7c5658de8d5fc93c4b63ab8d2347959a","width":1024,"height":512}},"lazy":false},{"type":"text","content":"U.S. Patent expands the scope of patent protection and increases the number of molecules that Enveric has the potential to develop or license for the treatment of neuropsychiatric conditions.","length":191,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., December 29, 2025--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced the issuance of U.S. Patent No. 12,492,179 entitled, "Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives" (the "‘179 patent"), with claims to compositions and methods of treatment for novel molecules with the potential to be developed for mental health disorders.","length":587,"tagName":"p"},{"type":"text","content":"The ‘179 patent expands the protection of Enveric’s pipeline of potentially neuroplastogenic and non-hallucinogenic molecules and strengthens the Company’s ability to target neuropsychiatric, neurological, and addiction disorders for patients with few options. With the new molecules, Enveric may be able to target key receptors in new ways, resulting in drug candidates with efficacy and safety profiles that were not previously achievable. The expanded pipeline of patent protected molecules provides additional opportunity for licensing and partnerships with pharmaceutical companies making investments in the neuropsychiatric field.","length":636,"tagName":"p"},{"type":"text","content":"In addition, for pharmaceutical corporations...